Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2
International Immunopharmacology · 2026-11 · 189 · 117399
DOI: 10.1016/j.intimp.2026.117399 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-11. Verfasst von Dongmei Hai und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China; Key Laboratory of Protection, Development, and Utilization of Medicinal Resou…. Hauptthemen laut MEDLINE: Acute Lung Injury, Neutrophils, Extracellular Traps, Anti-Inflammatory Agents. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Natural Science Foundation of Ningxia Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Acute lung injury (ALI) is a life-threatening inflammatory syndrome with limited pharmacological treatment options. Kumatakenin, a plant-derived flavonoid with recognized anti-inflammatory potential, has not been explored in inflammatory lung injury. Here, we investigated the protective effect of Kumatakenin in lipopolysaccharide (LPS)-induced ALI and examined the associated mechanism. Kumatakenin markedly alleviated lung injury, as evidenced by improved histopathology, reduced pulmonary edema, and decreased inflammatory cytokine production. It also attenuated neutrophil accumulation and activation in the lung, accompanied by suppression of neutrophil extracellular trap formation and oxidative stress. Mechanistically, Kumatakenin increased PRL2 protein abundance without altering its mRNA expression, suggesting post-transcriptional regulation. This effect was associated with reduced CMA-related PRL2 turnover, as indicated by decreased LAMP2A expression and weakened interaction of PRL2 with Hsc70 and LAMP2A. Moreover, pharmacological activation of CMA with QX77 largely reversed the effects of Kumatakenin on PRL2 protein abundance, oxidative stress, and NET formation. Collectively, these findings indicate that Kumatakenin alleviates LPS-induced ALI by interrupting neutrophil-driven inflammatory amplification and, at least in part, suppressing CMA-associated PRL2 degradation. This study highlights Kumatakenin as a promising natural lead compound for inflammatory lung disorders and identifies the CMA/PRL2 axis as a candidate therapeutic pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China; Key Laboratory of Protection, Development, and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Yinchuan 750004, China…
- Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Changsha 410013, Hunan, China; Hunan Provincial Key Laboratory of Cardiovascular Research, Central South University, Changsha 410013, Hunan, China.
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
- Ningxia Hui Autonomous Region People's Hospital, Yinchuan 750000, China.
- Key Laboratory of Ningxia Ethnomedicine Modernization, Ministry of Education, Ningxia Medical University, Yinchuan 750004, China.
Förderung
- Natural Science Foundation of Ningxia Province
- National Natural Science Foundation of China
Zitieren
APA
Hai, D., Zhu, X., Ye, S., Ma, L., Liu, Y., Wei, W., Zhang, M., Ma, X., Niu, Y., Peng, X., Yu, J., & Liu, N. (2026). Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2. International Immunopharmacology, 189, 117399. https://doi.org/10.1016/j.intimp.2026.117399
Vancouver
Hai D, Zhu X, Ye S, Ma L, Liu Y, Wei W, et al. Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2. International Immunopharmacology. 2026;189:117399. doi:10.1016/j.intimp.2026.117399
BibTeX
@article{Hai2026,
author = {Hai, Dongmei and Zhu, Xiaoyun and Ye, Saiya and Ma, Lin and Liu, Yue and Wei, Wei and Zhang, Mengting and Ma, Xueqing and Niu, Yang and Peng, Xiaodong and Yu, Jianqiang and Liu, Ning},
title = {Kumatakenin alleviates LPS-induced acute lung injury by attenuating pulmonary oxidative stress and neutrophil extracellular trap formation through CMA-associated regulation of PRL2},
journal = {International Immunopharmacology},
year = {2026},
volume = {189},
pages = {117399},
doi = {10.1016/j.intimp.2026.117399}
}
EUVIMED